A German-based KOL gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Topics discussed include the approval of CAR-T therapy for second-line patients as well as trials evaluating T-cell-directed bispecific antibodies for the first- and second-line settings. 

This interview was conducted on 28 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.